Search

Your search keyword '"Palau, Victoria E."' showing total 16 results
Start Over Author "Palau, Victoria E."
16 results on '"Palau, Victoria E."'

7. Covalent and Noncovalent Loading of Doxorubicin by Folic Acid-Carbon Dot Nanoparticles for Cancer Theranostics

Author

Dada, Samson N., primary, Babanyinah, Godwin K., additional, Tetteh, Michael T., additional, Palau, Victoria E., additional, Walls, Zachary F., additional, Krishnan, Koyamangalath, additional, Croft, Zacary, additional, Khan, Assad U., additional, Liu, Guoliang, additional, Wiese, Thomas E., additional, Glotser, Ellen, additional, and Mei, Hua, additional

Published
2022
Full Text
View/download PDF

8. Antiproliferative activity of 3,5,7- trihydroxy -6- methoxy flavone obtained from chromolaena leivensis (Hieron) on cancer cell lines of breast, prostate, lung, colon and cervix

Author

Torrenegra, Rubén Darío, Rodríguez, J., Rodríguez Aguirre, Oscar E., Palau, Victoria E., Méndez, Gina M., and Rodríguez Aguirre, Oscar Eduardo [0000-0002-5934-0451]

Subjects
Helichrysum, antiproliferative activity, Aceites Volátiles, Cancer cells, Plantas medicinales, Chromolaena, fungi, Neoplasias de la Mama, food and beverages, 3,5,7-trihidroxi-6-metoxi flavona, Próstata, 3,5,7-trihydroxy-6-methoxy flavone, Citotoxinas, heterocyclic compounds, Chromolaena leivensis
Abstract

The flavone 3,5,7-trihydroxy-6-methoxyflavone was isolated from leaf extracts of Chromolaena leivensis (Hieron), commonly named plant of cancer. It was identified based on their physicochemical propierties and spectroscopic data. This compound presented a methoxylation at C6, this is uncommon in flavonoids and which may confer some specificity of its biological activity. The cytotoxic activity of this flavonoid was determined on PC3 (prostate), MDA- MB-231 (breast), HT29 (colon), SiHa (cervix) and A549 (lung) cancer cells, using MTT assay, to assess if the flavonoid contributes to the anticancer activity previously proposed for Chromolaena leivensis. The cytotoxic activity of the 3,5,7-trihydroxy-6- methoxy flavone was similar to that obtained for the flavonoid quercetin but was low compared with the positive control vincristine sulphate. The better value of the inhibitory concentration of fifty percent (IC50) 150 μ M, was achieved on SiHa cell line, while the lower activity: 4008 μ M, was obtained on HT29 cancer cell line. However, severe morphological changes were detected on cytoskeleton and nucleus of the SiHa cells detected by immunofluorescence microscopy analysis of cells exposed to the half of the IC50 concentration obtained for the flavonoid. Data indicate that the flavonoid contributes to the anticancer activity of the extracts of leaves from Chromolaena leivensis, and could broadening the spectrum of flavonoids activity against various types of cancer non hormone-dependent.

Published
2016

12. Mechanism of Action of Two Flavone Isomers Targeting Cancer Cells with Varying Cell Differentiation Status

Author

LeJeune, Timothy M., primary, Tsui, Hei Yin, additional, Parsons, Laura B., additional, Miller, Gerald E., additional, Whitted, Crystal, additional, Lynch, Kayla E., additional, Ramsauer, Robert E., additional, Patel, Jasmine U., additional, Wyatt, Jarrett E., additional, Street, Doris S., additional, Adams, Carolyn B., additional, McPherson, Brian, additional, Tsui, Hei Man, additional, Evans, Julie A., additional, Livesay, Christopher, additional, Torrenegra, Ruben D., additional, and Palau, Victoria E., additional

Published
2015
Full Text
View/download PDF

14. Exacerbation of Celecoxib-Induced Renal Injury by Concomitant Administration of Misoprostol in Rats

Author

Cooper, Dustin L., primary, Murrell, Derek E., additional, Conder, Christopher M., additional, Palau, Victoria E., additional, Campbell, Grace E., additional, Lynch, Shaun P., additional, Denham, James W., additional, Hanley, Angela V., additional, Bullins, Kenny W., additional, Panus, Peter C., additional, Singh, Krishna, additional, and Harirforoosh, Sam, additional

Published
2014
Full Text
View/download PDF

16. Synergistic growth inhibition of PC3 prostate cancer cells with low-dose combinations of simvastatin and alendronate.

Author

Rogers M, Kalra S, Moukharskaya J, Chakraborty K, Niyazi M, Krishnan K, Lightner J, Brannon M, Stone WL, and Palau VE

Subjects
Apoptosis drug effects, Cell Line, Tumor, Dose-Response Relationship, Drug, Gene Expression Regulation, Neoplastic drug effects, Humans, JNK Mitogen-Activated Protein Kinases biosynthesis, Male, Prostatic Neoplasms genetics, Prostatic Neoplasms pathology, Proto-Oncogene Proteins c-akt biosynthesis, Alendronate administration & dosage, Drug Synergism, Prostatic Neoplasms drug therapy, Simvastatin administration & dosage
Abstract

The mevalonate pathway plays an important role in cancer biology and has been targeted with farnesyl transferase inhibitors, although their efficacy is limited due to significant adverse effects. Statins and bisphosphonates inhibit the mevalonate pathway at different steps, thus having negative effects at various levels on cancer cells. A combination of these drugs may result in an amplified cytotoxic effect and allow for use of significantly lower doses of the drugs involved. Statins inhibit the mevalonate pathway at 3-hydroxy-3-methylglutaryl coenzyme A reductase and bisphosphonates at farnesyl pyrophosphate synthase. Our results show that low-dose combinations of simvastatin and alendronate have a synergistic cytotoxic effect on androgen-independent prostate cancer PC-3 cells, but not on androgen-dependent LNCaP or DU 145 prostate cancer cells. These two drugs cause a sequential blockade of the mevalonate pathway and significantly affect survival and apoptotic pathways by down-regulating phospho-AKT and activating c-JUN and ERK., (Copyright© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.)

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results